How to buy Protalix BioTherapeutics stock | $1.19

Protalix BioTherapeutics Inc is a biotechnology business based in the US. Protalix BioTherapeutics shares (PLX) are listed on the NYSE MKT and all prices are listed in US Dollars. Protalix BioTherapeutics employs 207 staff and has a trailing 12-month revenue of around 0.00.

Protalix BioTherapeutics stock price (NYSE MKT: PLX)

Use our graph to track the performance of PLX stocks over time.

Protalix BioTherapeutics shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$1.19
52-week range	$1.14 - $7.02
50-day moving average	$1.39
200-day moving average	$2.41
Wall St. target price	$9.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.51

Buy Protalix BioTherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Protalix BioTherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Protalix BioTherapeutics price performance over time

Historical closes compared with the close of $1.19 from 2021-10-20

1 week (2021-10-15)	-3.25%
1 month (2021-09-22)	-11.85%
3 months (2021-07-22)	-28.74%
6 months (2021-04-22)	-79.93%

1 year (2020-10-21)	-66.67%
2 years (2019-10-21)	-52.96%
3 years (2018-10-19)	5.43
5 years (2016-10-21)	5

Is Protalix BioTherapeutics under- or over-valued?

Valuing Protalix BioTherapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Protalix BioTherapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Protalix BioTherapeutics's EBITDA

Protalix BioTherapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4 million.

The EBITDA is a measure of a Protalix BioTherapeutics's overall financial performance and is widely used to measure a its profitability.

Protalix BioTherapeutics financials

Revenue TTM	$48 million
Gross profit TTM	$52 million
Return on assets TTM	-8.76%
Return on equity TTM	0%
Profit margin	-43.21%
Book value	$0.08
Market capitalisation	$56 million

TTM: trailing 12 months

Shorting Protalix BioTherapeutics shares

There are currently 7.3 million Protalix BioTherapeutics shares held short by investors – that's known as Protalix BioTherapeutics's "short interest". This figure is 49.5% up from 4.9 million last month.

There are a few different ways that this level of interest in shorting Protalix BioTherapeutics shares can be evaluated.

Protalix BioTherapeutics's "short interest ratio" (SIR)

Protalix BioTherapeutics's "short interest ratio" (SIR) is the quantity of Protalix BioTherapeutics shares currently shorted divided by the average quantity of Protalix BioTherapeutics shares traded daily (recently around 1.2 million). Protalix BioTherapeutics's SIR currently stands at 6.25. In other words for every 100,000 Protalix BioTherapeutics shares traded daily on the market, roughly 6250 shares are currently held short.

However Protalix BioTherapeutics's short interest can also be evaluated against the total number of Protalix BioTherapeutics shares, or, against the total number of tradable Protalix BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Protalix BioTherapeutics's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Protalix BioTherapeutics shares in existence, roughly 160 shares are currently held short) or 0.222% of the tradable shares (for every 100,000 tradable Protalix BioTherapeutics shares, roughly 222 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Protalix BioTherapeutics.

Find out more about how you can short Protalix BioTherapeutics stock.

Protalix BioTherapeutics share dividends

We're not expecting Protalix BioTherapeutics to pay a dividend over the next 12 months.

Have Protalix BioTherapeutics's shares ever split?

Protalix BioTherapeutics's shares were split on a 1:10 basis on 19 December 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Protalix BioTherapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Protalix BioTherapeutics shares which in turn could have impacted Protalix BioTherapeutics's share price.

Protalix BioTherapeutics share price volatility

Over the last 12 months, Protalix BioTherapeutics's shares have ranged in value from as little as $1.14 up to $7.02. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Protalix BioTherapeutics's is 2.6794. This would suggest that Protalix BioTherapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Protalix BioTherapeutics overview

Protalix BioTherapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S. p. A.

Frequently asked questions

What percentage of Protalix BioTherapeutics is owned by insiders or institutions?
Currently 24.06% of Protalix BioTherapeutics shares are held by insiders and 10.888% by institutions. How many people work for Protalix BioTherapeutics?
Latest data suggests 207 work at Protalix BioTherapeutics. When does the fiscal year end for Protalix BioTherapeutics?
Protalix BioTherapeutics's fiscal year ends in December. Where is Protalix BioTherapeutics based?
Protalix BioTherapeutics's address is: 2 University Plaza, Hackensack, NJ, United States, 07601 What is Protalix BioTherapeutics's ISIN number?
Protalix BioTherapeutics's international securities identification number is: US74365A3095 What is Protalix BioTherapeutics's CUSIP number?
Protalix BioTherapeutics's Committee on Uniform Securities Identification Procedures number is: 68750Q101